This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CEL-SCI Corporation Reports Second Quarter 2012 Financial Results

CEL-SCI Corporation (NYSE AMEX: CVM) announced today financial results for the fiscal quarter ended March 31, 2012.

CEL-SCI reported that net loss available to common shareholders for the quarter ended March 31, 2012 was $(10,086,959) versus $(15,097,973) during the same quarter ended March 31, 2011. Net loss per common share, (basic) was $(0.04) for the quarter ended March 31, 2012 versus $(0.07) during the same quarter ended March 31, 2011. The operating loss for the quarter ended March 31, 2012 was $(4,262,357) versus $(5,096,996) during the same quarter ended March 31, 2011. Net loss available to common shareholders for the six months ended March 31, 2012 was $(14,243,792) versus $(21,348,925) million during the same six months ended March 31, 2011. Net loss per common share, (basic) was $(0.06) for the six months ended March 31, 2012 versus $($0.10) during the same six months ended March 31, 2011. The operating loss for the six months ended March 31, 2012 was $(8,705,633) versus $(9,413,030) during the same six months ended March 31, 2011.

R&D expenses for the quarter ended March 31, 2012 totaled $2,594,235 versus R&D expenses of $3,042,097 for the quarter ended March 31, 2011. R&D expenses for the six months ended March 31, 2012 totaled $5,050,420 versus R&D expenses of $6,306,525 for the six months ended March 31, 2011. R&D expenses related to the running of the Company’s Phase III clinical trial declined because of lower Multikine manufacturing expenditures and lower costs related to the set-up of the clinical sites that had been present in the same period last year.

Geert Kersten, Chief Executive Officer, said, “Our global Phase III clinical trial for our investigational cancer drug Multikine is moving forward as anticipated. We continue to believe that we will end up being successful in this trial and that we will develop a paradigm shift in the way that head and neck cancer is treated.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs